A clinical-stage biotechnology company focused on developing immunotherapies targeting autoimmune and inflammatory diseases. Its lead candidate, MIS416, has been studied as a potential treatment for progressive multiple sclerosis by modulating innate immune pathways. Investors have followed the comp...
2 members of Congress have disclosed 5 trades in Innate Immunotherapeutics Ltd (IILT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 4 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-09-18 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2017-08-22 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2017-08-21 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2016-01-14 | JAMES B. RENACCI | buy | $1K – $15K |
| 2015-02-26 | MICHAEL T. MCCAUL | sell | $1K – $15K |